Company intelligence / Profile preview

Calibrate

New York, New York, United States

Ownership: Private
Employees: ~373
Development stage: Other

Overview

Calibrate offers a commercial digital health program combining FDA-approved GLP-1 agonist medications (such as semaglutide, e.g., Wegovy) with intensive lifestyle coaching and support, reporting sustained average weight loss of 14% to over 19% in its members over one to three years. The approach integrates virtual physician visits, bi-weekly coaching, and a scalable digital interface for sustained metabolic health improvement.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculeHormone
Industry: Non-Academic Healthcare

Partnerships

OptumRx (UnitedHealth Group subsidiary)

Beyond the preview

Go deeper on Calibrate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calibrate.

Explore the full profile